The evolving role of germline genetic testing and management in prostate cancer: Report from the princess margaret cancer centre international retreat

Roderick Clark, Miran Kenk, Kristen McAlpine, Emily Thain, Kirsten M. Farncombe, Colin C. Pritchard, Robert Nussbaum, Alexander W. Wyatt, Johann de Bono, Danny Vesprini, Yvonne Bombard, Justin Lorentz, Steven Narod, Raymond Kim, Neil Fleshner

Research output: Contribution to journalReview articlepeer-review

4 Scopus citations

Abstract

Introduction: Prostate cancer is a significant cause of cancer mortality. It has been well-established that certain germline pathogenic variants confer both an increased risk of being diagnosed with prostate cancer and dying of prostate cancer.1 There are exciting developments in both the availability of genetic testing and opportunities for improved treatment of patients. On August 19, 2020, the Princess Margaret Cancer Centre in Toronto, Ontario, hosted a virtual retreat, bringing together international experts in urology, medical oncology, radiation oncology, medical genetics, and translational research, as well as a patient representative. We are pleased to provide this manuscript as a review of those proceedings for Canadian clinicians.

Original languageEnglish (US)
JournalJournal of the Canadian Urological Association
Volume15
Issue number12
DOIs
StatePublished - Jun 2021

All Science Journal Classification (ASJC) codes

  • Urology

Fingerprint

Dive into the research topics of 'The evolving role of germline genetic testing and management in prostate cancer: Report from the princess margaret cancer centre international retreat'. Together they form a unique fingerprint.

Cite this